Podcasts about pharmaceutical outcomes

Ronny Bell, PhD, MS, is chair of the Division of Pharmaceutical Outcomes and Policy and the Fred Eshelman Distinguished Professor. His research focuses on health disparities in cancer as well as a concentration in chronic disease disparities with an emphasis on rural and underserved populations. As an enrolled member of the Lumbee tribe of eastern North Carolina, and Chair of the North Carolina American Indian Health Board, he is particularly interested in factors that contribute to health disparities in American Indian populations. Read more at https://pharmacy.unc.edu/directory/bellr/

In this Complex Care Journal Club podcast episode, Dr. Kathleen C. Thomas discusses a cross-sectional study of associations between neighborhood context with psychotropic polypharmacy and psychotherapy among children with high-needs for medical or psychiatric care. She describes the inclusion of parent advisors on the study team, the inclusion of children with medical complexity in the study population, key insights including the importance of non-medical supports, and the next steps from this work. SPEAKER Kathleen C. Thomas, PhD, MPH Professor and Vice Chair of Research and Graduate Education Division of Pharmaceutical Outcomes and Policy Eshelman School of Pharmacy University of North Carolina at Chapel Hill HOST Kristina Malik, MD Assistant Professor of Pediatrics, University of Colorado School of Medicine Medical Director, KidStreet Pediatrician, Special Care Clinic, Children's Hospital Colorado DATE Initial publication date: January 13, 2025. ARTICLE REFERENCED Thomas KC, Annis IE, deJong NA, Christian RB, Davis SA, Hughes PM, Prichard BA, Prichard JR, Allen PS, Gettinger JS, Morris DN, Eaker KB. Association Between Neighborhood Context and Psychotropic Polypharmacy Use Among High-Need Children. Psychiatr Serv. 2024 Sep 11:appips20230639. doi: 10.1176/appi.ps.20230639. Epub ahead of print. PMID: 39257315. TRANSCRIPT https://cdn.bfldr.com/D6LGWP8S/as/3rffshwp3q2km53w7xckq38/011025_CCJCP__Where_You_Live_Matters Clinicians across healthcare professions, advocates, researchers, and patients/families are all encouraged to engage and provide feedback! You can recommend an article for discussion using this form: forms.gle/Bdxb86Sw5qq1uFhW6 Please visit: http://www.openpediatrics.org OPENPediatrics™ is an interactive digital learning platform for healthcare clinicians sponsored by Boston Children's Hospital and in collaboration with the World Federation of Pediatric Intensive and Critical Care Societies. It is designed to promote the exchange of knowledge between healthcare providers around the world caring for critically ill children in all resource settings. The content includes internationally recognized experts teaching the full range of topics on the care of critically ill children. All content is peer-reviewed and open access-and thus at no expense to the user. For further information on how to enroll, please email: openpediatrics@childrens.harvard.edu CITATION Thomas KC, Malik KE. Where You Live Matters: Psychotropic Polypharmacy and Psychotherapy in Children with High-Needs‌. 01/2025. OPENPediatrics. Online Podcast. https://soundcloud.com/openpediatrics/where-you-live-matters-psychotropic-polypharmacy-and-psychotherapy-in-children-with-high-needs.

In episode three of our Community-based Solutions for Substance Use Challenges season, Just Science sits down with Dr. Chris Delcher, Associate Professor in the Department of Pharmacy Practice and Science and Director of the Institute for Pharmaceutical Outcomes and Policy at the University of Kentucky, to discuss how his team tracks community drug use through wastewater analysis. Much like analyzing a urine sample to determine what drugs an individual is using, analyzing wastewater from a community offers insight into drug trends across an entire region of people. The NIJ-funded weTEST program allows for the collection and analysis of wastewater from rest areas and truck stops in Kentucky to track current drug trends in a timely manner. Listen along as Dr. Delcher discusses his inspiration for using wastewater to monitor drug use, the sometimes-messy process of collecting wastewater samples, and how scientists approach ethical considerations that come with collecting data from wastewater systems. This Just Science season is supported, in part, by RTI Award No. 15PNIJ-21-GK-02192-MUMU, awarded by the National Institute of Justice, and by RTI Award No. 15PBJA-23-GK-02250-COAP, awarded by the Bureau of Justice Assistance. Both are agencies within the Office of Justice Programs, U.S. Department of Justice.

On today's episode, meet Dr. Ronny Bell, the Fred Eshelman Professor and Chair of the Division of Pharmaceutical Outcomes and Policy at the Eshelman School of Pharmacy at UNC Chapel Hill. Dr. Bell received his undergraduate degree in Public Health Nutrition from the University of North Carolina at Chapel Hill School of Public Health and his Master's and Doctorate in Foods and Nutrition from the University of North Carolina at Greensboro. Dr. Bell completed a post-doctoral fellowship in Gerontology and completed a Master's in Epidemiology from the Wake Forest School of Medicine. From 1996 – 2016, Dr. Bell was a member of the faculty in the Department of Epidemiology at Wake Forest, and from 2006 – 2016, he served as Director of the Maya Angelou Center for Health Equity. From 2016 – 2020, Dr. Bell served as Chair of the Department of Public Health in the Brody School of Medicine at East Carolina University. Dr. Bell is an enrolled member of the Lumbee tribe of eastern North Carolina, and currently serves a Chair of the North Carolina American Indian Health Board. He also serves as co-lead the Southeastern American Indian Cancer Health Equity Partnership (SAICEP). Among his awards and honors, Dr. Bell was most recently appointed to U.S. Department of Health and Human Services Advisory Committee on Minority Health (2024).

Twenty years ago, scientists found that phenylephrine, listed as a decongestant in many cold medicines, didn't work. What can you use instead? In September, an advisory committee for the Food and Drug Administration unanimously confirmed that phenylephrine—a common ingredient in cold medicines, including some types of Mucinex and Robitussin—doesn't work.For many physicians, pharmacists, and cold-sufferers, this came as no surprise. Phenylephrine's ineffectiveness had been an open secret in the healthcare community for decades.In 2005, Dr. Randy Hatton, clinical professor at the Pharmaceutical Outcomes and Policy Department at the University of Florida, managed the University of Florida Drug Information and Pharmacy Resource Center hotline. He often received calls from pharmacists reporting that phenylephrine-based drugs had no effect on improving colds.He came across research from Dr. Leslie Hendeles, professor emeritus of the College of Pharmacy, also at the University of Florida, from a decade prior. Dr. Hendeles had also found that the substance was ineffective. They partnered up and petitioned the FDA to publicly confirm their finding. Their collaboration was the first step toward the FDA's recent announcement.But despite the announcement, the removal of these drugs from shelves is not guaranteed. Pharmaceutical companies are appealing the FDA's decision, and are trying to stall an official declaration that prohibits their sale.Guest host Flora Lichtman talks with Dr. Hatton and Dr. Hendeles about the long road to the FDA's announcement.They discuss how their research proved phenylephrine's ineffectiveness, and which drugs people can turn to instead as cold season approaches.To stay updated on all things science, sign up for Science Friday's newsletters. Transcripts for each segment will be available the week after the show airs on sciencefriday.com.

Today we take a deep dive into something we really haven't covered on the Hack My Age podcast. Rheumatoid arthritis. And we learn more about it from Indira Pulliadath who had her own struggles with rheumatoid arthritis and actually changed her profession as a pharmaeconomics researcher to a nutritional therapy practitioner (NTP) because of it. She also has a Master's in Pharmaceutical Outcomes and Policy. But with all the knowledge she had on pharmaceuticals, she still found that medication alone wasn't enough when her arthritis was so bad, she could hardly function. So she started looking into healing diets, which worked so well it motivated her to switch careers and move into the nutrition world. Indira has since wrote a great cookbook, called 'AIP Indian Fusion', which has autoimmune protocol recipes inspired by Indian cuisine. You can also find her healthy recipes on her blog 'Cook2Nourish'. I will have links to all of Indira's information in the shownotes. Group coaching program for RA: https://www.rheumatoidstrong.com/rheumatoid-strong-plus Self-paced online course for RA: https://www.rheumatoidstrong.com/rheumatoid-strong AIP cookbook: https://www.rheumatoidstrong.com/cookbook Discount code: ZORA for 10% off programs Indira currently offers group nutritional coaching sessions to clients living with RA. Her program is called ‘Rheumatoid Strong' and is available as a self-paced online course or as a group coaching program. To check out her programs, visit www.rheumatoidstrong.com. Indira is also the author of the cookbook , 'AIP Indian Fusion', which consists of AIP recipes that are highly inspired by Indian cuisine. You can find her healthy recipes on her blog 'Cook2Nourish' (www.cook2nourish.com) and on her Youtube channel(https://www.youtube.com/c/Cook2Nourish).   Contact Indira: Instagram: www.instagram.com/cook2nourish Instagram: www.instagram.com/rheumatoidstrong Youtube: https://www.youtube.com/@Cook2Nourish/ Email: cook2nourish@gmail.com MENOPAUSE ENERGY REBOOT PROGRAM ⁠Group program⁠ starting October 1, 2023 https://hackmyage.com/energy-reboot/ ⁠Self guided program⁠ https://hackmyage.com/energy-reboot-self-guided/ Use code EARLYBIRD for 30% off until September 12, 2023 Join the Hack My Age community on: Facebook Page : ⁠⁠⁠http://facebook.com/hackmyage⁠⁠⁠ Facebook Group: Biohacking Menopause Instagram: ⁠⁠⁠http://instagram.com/hackmyage⁠⁠⁠ Website: ⁠⁠⁠http://www.hackmyage.com⁠⁠⁠ Hack My Age VIP Group: ⁠⁠⁠http://patreon.com/hackmyage⁠⁠⁠ Email: zora@hackmyage.com Newsletter: ⁠⁠⁠http://www.hackmyage.com/newsletter⁠⁠⁠ This podcast is edited by ⁠⁠⁠jonathanjk.com⁠ --- Send in a voice message: https://podcasters.spotify.com/pod/show/hackmyage/message Support this podcast: https://podcasters.spotify.com/pod/show/hackmyage/support

In this week's episode, Carina Dolan, PharmD, BCOP, senior director for Clinical Oncology and Pharmaceutical Outcomes at Vizient Inc, discusses the highlights and big picture moving forward for hospitals and health-system pharmacies.

Whose job is it to teach risk management principles to pharmacy learners? Sure – they have to take a law course as part of their curricular requirements, but how much does that mean to them until they are in real life situations as part of their IPPEs, APPEs, or residency? As preceptors, it's important that we not only recognize and manage the legal risks of welcoming pharmacy learners within our pharmacy practice but also that we are prepared to teach practical concepts such as risk management in addition to developing their clinical skills. Listen to this episode where we talk with David Brushwood, a well-known expert, and educator in the practical and professional aspects of risk management and pharmacy law.HostKathy Schott, PhDCEimpact GuestsDavid Brushwood, RPh, JDSenior Lecturer, University of Wyoming School of PharmacyProfessor Emeritus, University of FloridaContent Development, CEimpactDavid Brushwood graduated with degrees in pharmacy and law from the University of Kansas.  He practiced both professions prior to entering academia.  David retired from the University of Florida, College of Pharmacy, in 2014 where he is currently Professor Emeritus of Pharmaceutical Outcomes and Policy.  In 2015, David joined the faculty at the University of Wyoming, School of Pharmacy, and he serves there as a Senior Lecturer teaching online courses in the Master of Science in Health Services Administration program.  David is a pharmacy law content developer with CEimpact, where he produces educational programs for pharmacists, pharmacy technicians, and pharmacy students. David's primary research interests are pain management policy, patient safety regulation, and pharmacist professional responsibility. Get CEClick here to access the courseCE InformationAt the end of this course, preceptors will be able to:1.     Describe situations where exposure to malpractice liability may occur for preceptors during experiential learning2.     Discuss techniques for teaching risk management to pharmacy learners in the experiential learning setting UAN: 0107-0000-22-422-H99-P Release Date: 11/16/2022 Expiration Date: 11/16/2025The speakers have no relevant financial relationships with ineligible companies to disclose.This program has been:Approved by the Minnesota Board of Pharmacy as education for Minnesota pharmacy preceptors.Reviewed by the Texas Consortium on Experiential Programs and has been designated as preceptor education and training for Texas preceptors. Want more information on this and related topics? Avoiding Malpractice Liability with Effective Teaching StrategiesFERPA: A Guide for PreceptorsAdvanced Certificates in Risk Management:For IPPE StudentsFor APPE StudentsFor Pharmacy ResidentsPharmacist-In-Charge BootcampFollow CEimpact on Social Media:LinkedInInstagramDownload the CEimpact App for Free Continuing Education + so much more!

Carina Dolan, Editor in Chief of Vizient's Pharmacy Market Outlook and Senior Director of Clinical Oncology and Pharmaceutical Outcomes at Vizient, shares insights on the Summer 2022 Vizient Pharmacy Market Outlook with host Gretchen Brummel. Carina discusses the outlook's projection, impact of inflation, and ways that frontline staff can use the report.   Guest speakers: Carina Dolan, PharmD, MS, BCOP Senior Director of Clinical Oncology and Pharmaceutical Outcomes  Vizient   Moderator: Gretchen Brummel, PharmD, BCPS Pharmacy Executive Director Vizient Center for Pharmacy Practice Excellence   Show Notes: [00:45-1:21] Final Projection for this issue [01:22-1:57] Highlights from this issue [01:58-2:48] How inflation currently impacts drug prices and projections [02:49-3:34] How frontline staff can use outlook [03:35-4:16] Unexpected trends emerging [04:17-5:03] Key forecast issues   [05:04-5:35] Where listeners can go for more detailed information   Links | Resources: Vizient Pharmacy Market Outlook Member link: Click Here   Vizient Pharmacy Market Outlook highlights public version: Click Here   Subscribe Today! Apple Podcasts Amazon Podcasts Google Podcasts Spotify Stitcher Android RSS Feed

Almut Winterstein, RPh, PhD, FISPE, is the Professor and Chair of the Department of Pharmaceutical Outcomes and Policy, the Dr. Robert and Barbara Crisafi Chair for Medication Safety, and director of the Center for Drug Evaluation and Safety at the University of Florida College of Pharmacy.As an expert in drug safety she has chaired the Food and Drug Administration's Drug Safety and Risk Management Advisory Committee. She also leads the Consortium for Medical Marijuana Clinical Outcomes Research created by Florida's state legislature. I learned so much in talking with her and think you will as well!

Carina Dolan, Editor in Chief of Vizient's Pharmacy Market Outlook and Senior Director of Clinical Oncology and Pharmaceutical Outcomes at Vizient, shares insights on January's Vizient Pharmacy Market Outlook with host Gretchen Brummel. Carina discusses the outlook's accuracy, ways that frontline staff can use the report, and the values members can get out of the results.   Guest speakers: Carina Dolan, PharmD, MS, BCOP Senior Director of Clinical Oncology and Pharmaceutical Outcomes  Vizient Moderator: Gretchen Brummel, PharmD, BCPS Pharmacy Executive Director Vizient Center for Pharmacy Practice Excellence   Show Notes: [00:49-1:24] Outlook refresher [01:25-2:14] What is different in this version [02:15-3:51] Grading past projections [03:52-4:33] How frontline staff can use outlook [04:34-5:28] What surprises are in this version? [05:29-7:00] New topics in this version   [07:01-10:39] The future forecasts and other useful resources   Links | Resources: Vizient Pharmacy Market Outlook Member link Click here Vizient Pharmacy Market Outlook highlights public version Click here   Subscribe Today! Apple Podcasts Amazon Podcasts Google Podcasts Spotify Stitcher Android RSS Feed

Vizient publishes the Pharmacy Market Outlook twice a year to project drug prices and key market trends for the next 18-months.  Pharmacists use this information to budget and project their supply needs.  Carina Dolan, Senior Director for Clinical Oncology and Pharmaceutical Outcomes at Vizient shares details revealed in the summer 2021 edition of the Pharmacy Market Outlook.    Guest speaker: Carina Dolan, PharmD, MS, BCOP Senior Director for Clinical Oncology and Pharmaceutical Outcomes Pharmacy Solutions Vizient   Moderator: Gretchen Brummel, PharmD, BCPS Pharmacy Executive Director Vizient Center for Pharmacy Practice Excellence   Show Notes: [1:16] The Pharmacy Market Outlook is a bi-annual report that projects drug prices for 18 months, and reviews the trends of the various market segments. [2:08] How the report is calculated [2:45] Purchases made through 340B program and direct or outsourced purchases made by hospitals are not included in the Pharmacy Market Outlook. [3:02] Prediction of the drug price inflation rate for January – December 2022 [3:38] How the Vizient Pharmacy Market Outlook compares to other drug forecasting reports. [4:01] The estimate drug price inflation rate for the upcoming calendar year is anticipated to have a moderate price increase. [4:30] The largest contributor to drug price increases is at Adalimumab and will remain that way until 2023. [4:49] The Vizient Drug Price Forecast Report in the Vizient Savings Actualyzer can help you with your budget. It pulls your wholesale purchase data and self-populates the projections of the report. It has the capability to use your institutes direct purchases. [5:25] Closer Look features the different segments of the market including acute care, non-acute care, specialty pharmaceuticals and pediatrics. [5:34] The report has a projected timeline graphic that shows investigational medications likely to be approved and other events likely to happen during the 18-month timeframe.   [6:40] The current, high-priority advocacy topics include 340B pricing for contract pharmacies, white-bagging for provider-administered medications, the unapproved drugs initiative (UDI) and changes to the FDA enforcement of Action. [7:25] Accelerated Approval Pathways [7:25] Example: Aducanumab, brand name: Adulhelm, for the treatment of Alzheimer's disease   [9:10] New topic highlighted is therapeutic class (i.e. diabetes and related medications) [9:52] Vizient members can access the report online through the website at Vizientinc.com/pharmacysolutions.com, then go to My Dashboard to access the Vizient Pharmacy Market Outlook report. [10:06] Non-Vizient members can access a public version on the VizientInc.com [10:15] The drug budget report may be accessed through the Vizient Savings Actualyzer Pharmacy. [10:20] If you have issues accessing the report or other questions, please email PharmacyQuestions@Vizientinc.com   Links | Resources: Vizient Pharmacy Market Outlook - member version Click here Vizient Pharmacy Market Outlook highlights - public version Click here   Subscribe Today! Apple Podcasts Google Podcasts Spotify Stitcher Android RSS Feed

Did you know that behind the decisions of legislators there are many people paying the consequences? Sometimes, laws associated with health services, which real objective is to reduce critical problems related to them, can strongly affect patients and the way they face their diseases. Dr. Juan Hincapie Castillo joins us to discuss the restriction of opioids medications and both positive and negative consequences that this legislative decision has on the general population. He will also talk about the actual problem of illicit opioid overdoses, the use of fentanyl substances and what are the trends that are happening while these laws are implemented. Dr. Juan M. Hincapie-Castillo, Pharm.D, M.S., Ph.D., joined the Department of Pharmaceutical Outcomes and Policy as an assistant professor in 2019. He has received the degrees of Doctor of Pharmacy (2013), Master of Science in Pharmaceutical Sciences (2017), and Ph.D. with a concentration in Pharmacoepidemiology (2019) at the University of Florida College of Pharmacy. His research interests include the study of drug utilization and safety in the area of pain management, the evaluation of the effects of State and Federal laws on patient outcomes, and the assessment of patient safety and quality for inpatient pain management.

Did you know that behind the decisions of legislators there are many people paying the consequences? Sometimes, laws associated with health services, which real objective is to reduce critical problems related to them, can strongly affect patients and the way they face their diseases. Juan Hincapie Castillo joins us to discuss the restriction of opioids medications and both positive and negative consequences that this legislative decision has on the general population. He will also talk about the actual problem of illicit opioid overdoses, the use of fentanyl substances and what are the trends that are happening while these laws are implemented. ABOUT TODAY'S GUEST - Juan M. Hincapie-Castillo, Pharm.D, M.S., Ph.D Juan M. Hincapie-Castillo, Pharm.D, M.S., Ph.D., joined the Department of Pharmaceutical Outcomes and Policy as an assistant professor in 2019. He has received the degrees of Doctor of Pharmacy (2013), Master of Science in Pharmaceutical Sciences (2017), and Ph.D. with a concentration in Pharmacoepidemiology (2019) at the University of Florida College of Pharmacy. His research interests include the study of drug utilization and safety in the area of pain management, the evaluation of the effects of State and Federal laws on patient outcomes, and the assessment of patient safety and quality for inpatient pain management.

Episode 47: This Friday's interview is the 24th installment in the Entrepreneurship and Financial Literacy block of podcasts. ⁣ ⁣It will focus on the theme

Date:10/17/2008Length: 00:07:52Size: 3.60MBProgram Representative: David B. Brushwood, R.Ph., J.D., Professor of Pharmaceutical Outcomes and Policy, University of FloridaIn this episode, Professor Brushwood provides an update on a new online dual-degree program: a Master of Science in Pharmacy degree from the University of Florida and a Master of Business Administration from Stetson University. He discusses the benefits of the dynamic dual-degree, the program structure, the advantages of an online program, and admission requirements. Current registration period ends after November 1, 2008.Play PodcastFor more information on how you can be featured in a podcast, contact Dan Limbach at dlimbach@pharmavoice.com or call him at (847) 594-0157 .

Date:6/16/2008Length: 00:09:10Size: 4.2MBThought Leader: David B. Brushwood, R.Ph., J.D., Professor of Pharmaceutical Outcomes and Policy, University of FloridaIn this episode, Professor Brushwood provides an overview of a new online dual-degree program: a Master of Science in Pharmacy degree from the University of Florida and a Master of Business Administration from Stetson University. He discusses the benefits of the dynamic dual-degree, the program structure, the advantages of an online program, and admission requirements.Play PodcastFor more information on how you can be featured in a podcast, contact Dan Limbach at dlimbach@pharmavoice.com or call him at (847) 594-0157.